List of works - Tung M Fong

1-Sulfonyl-4-acylpiperazines as selective cannabinoid-1 receptor (CB1R) inverse agonists for the treatment of obesity

scientific article published in April 2009

Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents

scientific article

Cannabinoid-1 receptor inhibition prevents the reduction of 24-hour energy expenditure with weight loss

scientific article published on 14 October 2011

Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents

scientific article published on 25 October 2007

Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation

scientific article published on 21 April 2010

Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity

scientific article

Discovery of potent, selective, and orally bioavailable 3H-spiro[isobenzofuran-1,4'-piperidine] based melanocortin subtype-4 receptor agonists

scientific article published on 17 June 2010

Furo[2,3-b]pyridine-based cannabinoid-1 receptor inverse agonists: synthesis and biological evaluation. Part 1.

scientific article published on 4 January 2010

Interactions of human melanocortin 4 receptor with nonpeptide and peptide agonists

scientific article

Lack of protection with a novel, selective melanocortin receptor subtype-4 agonist RY767 in a rat transient middle cerebral artery occlusion stroke model

scientific article published on 4 December 2008

Melanocortin-4 receptor (MC4R) agonists for the treatment of obesity

scientific article published on July 2006

Optimization of privileged structures for selective and potent melanocortin subtype-4 receptor ligands

scientific article published on 10 June 2010

Pyridopyrimidine based cannabinoid-1 receptor inverse agonists: Synthesis and biological evaluation

scientific article published on 9 March 2009

Regulation of energy homeostasis by bombesin receptor subtype-3: selective receptor agonists for the treatment of obesity

scientific article published on 21 January 2010

Substituted acyclic sulfonamides as human cannabinoid-1 receptor inverse agonists

scientific article

Synthesis and SAR of 5,6-diarylpyridines as human CB1 inverse agonists

scientific article published in February 2005

The mu-opioid receptor subtype is required for the anorectic effect of an opioid receptor antagonist

scientific article published on 5 July 2006

The role of melanocortins in body weight regulation: opportunities for the treatment of obesity

scientific article

The triple uptake inhibitor (1R,5S)-(+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0] hexane hydrochloride (DOV 21947) reduces body weight and plasma triglycerides in rodent models of diet-induced obesity

scientific article

List of works by Tung M Fong

1-Sulfonyl-4-acylpiperazines as selective cannabinoid-1 receptor (CB1R) inverse agonists for the treatment of obesity

Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents

Cannabinoid-1 receptor inhibition prevents the reduction of 24-hour energy expenditure with weight loss

Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents

Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation

Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity

Discovery of potent, selective, and orally bioavailable 3H-spiro[isobenzofuran-1,4'-piperidine] based melanocortin subtype-4 receptor agonists

Furo[2,3-b]pyridine-based cannabinoid-1 receptor inverse agonists: synthesis and biological evaluation. Part 1.

Interactions of human melanocortin 4 receptor with nonpeptide and peptide agonists

Lack of protection with a novel, selective melanocortin receptor subtype-4 agonist RY767 in a rat transient middle cerebral artery occlusion stroke model

Melanocortin-4 receptor (MC4R) agonists for the treatment of obesity

Optimization of privileged structures for selective and potent melanocortin subtype-4 receptor ligands

Pyridopyrimidine based cannabinoid-1 receptor inverse agonists: Synthesis and biological evaluation

Regulation of energy homeostasis by bombesin receptor subtype-3: selective receptor agonists for the treatment of obesity

Substituted acyclic sulfonamides as human cannabinoid-1 receptor inverse agonists

Synthesis and SAR of 5,6-diarylpyridines as human CB1 inverse agonists

The mu-opioid receptor subtype is required for the anorectic effect of an opioid receptor antagonist

The role of melanocortins in body weight regulation: opportunities for the treatment of obesity

The triple uptake inhibitor (1R,5S)-(+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0] hexane hydrochloride (DOV 21947) reduces body weight and plasma triglycerides in rodent models of diet-induced obesity